-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

Benzinga·11/15/2024 09:51:34
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $9 price target.